TOP TEN perturbations for 40873_at (Homo sapiens)

Organism: Homo sapiens
Gene: 40873_at
Selected probe(set): 201908_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 40873_at (201908_at) across 6672 perturbations tested by GENEVESTIGATOR:

expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) / expO ovary cancer study 1 (carcinoma, NOS; metastatic)

Relative Expression (log2-ratio):-2.5027819
Number of Samples:2 / 5
Experimental expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary.
Control expO ovary cancer study 1 (carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary carcinoma (NOS) of the ovary.

expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) / expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)

Relative Expression (log2-ratio):-2.4992857
Number of Samples:2 / 4
Experimental expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary.
Control expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary clear cell adenocarcinoma (NOS) of the ovary.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):2.4577036
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):2.1683073
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):2.135621
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H9N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):2.0892954
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):2.0693665
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

pancreatic islet study 3 (re-differentiated; PPRF; 2d) / normal pancreatic islet sample

Relative Expression (log2-ratio):2.0186787
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 2d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 2 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

sarcoidosis study 6 (orbital adipose tissue) / normal orbital adipose tissue

Relative Expression (log2-ratio):-2.0006666
Number of Samples:7 / 22
Experimental sarcoidosis study 6 (orbital adipose tissue)
Orbital adipose tissue samples obtained from patients who suffered from sarcoidosis. Biopsies were formalin-fixed and paraffin-embedded.
Control normal orbital adipose tissue
Normal orbital adipose tissue samples. Samples were obtained from subjects with no history of orbital disease at the time of surgery such as fat typically excised and discarded as part of routine blepharoplasty or retrobulbar fat that is snared with the eye during enucleation. Biopsies were formalin-fixed and paraffin-embedded.

expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)

Relative Expression (log2-ratio):1.928834
Number of Samples:51 / 2
Experimental expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the ovary.
Control expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary.